Some people stay on Entyvio for 14 weeks and some stay on Entyvio for a year or even longer.
If after 14 weeks of being on Entyvio, you do not have a therapeutic benefit with Entyvio your doctor may discontinue your Entyvio treatment.
Entyvio is usually given and administered every 8 weeks which is about 6 doses per year.
Entyvio does not have a black box warning as it's selective in it's targeting, even though it is administered intravenously.
After an Entyvio Infusion you may sometimes drive as long as you're not dizzy.
It's best to wait awhile after taking Entyvio to see how you feel before you drive as some people have reported feeling dizzy after taking Entyvio and some people don't get dizzy or the dizziness goes away after awhile.
The Entyvio medication is pretty expensive and costs around $6,700.00 for a supply of one 300 mg vial of powder for injection.
Entyvio is an injection and is given as an injection just under the skin.
High Blood Pressure is a side effect of ENTYVIO for some people.
Entyvio can be administered at home.
Entyvio was approved as a self-injectable subcutaneous format for at-home maintenance treatment of adult patients 18 years or older with moderately to severely active ulcerative colitis.
The medicine ENTYVIO is owned by and made by Millennium Pharmaceuticals, Inc.
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease.
Entyvio was launched in both the U.S. and E.U. market in June 2014 and has been on the market for over 7 years in those countries.
Entyvio, from Takeda Pharmaceuticals, was first approved by the U.S. Food and Drug Administration (FDA) on May 20, 2014.
ENTYVIO (vedolizumab), an integrin receptor antagonist, is a humanized IgG1 monoclonal antibody produced in Chinese hamster ovary cells that binds to the human α4β7 integrin.
ENTYVIO has an approximate molecular weight of 147 kilodaltons.
The FDA approved ENTYVIO based on evidence from two clinical trials in patients with moderate to severe ulcerative colitis.
The trials were conducted in 34 countries around the world.
Entyvio isn't a systemic immunosuppressant. (Systemic drugs affect your whole body.)
Entyvio has a selective effect on your gut. It doesn't affect your entire immune system.
Entyvio contains the drug vedolizumab. Vedolizumab isn't available as a generic drug.
It's only available as Entyvio.